Bayer punktet mit Zulassung in China, Analysten heben direkt Kursziele an

Bayer erhält eine Zulassung in China für ein Krebsmedikament, das nun erstmals ohne Chemotherapie eingesetzt werden darf. Analysten zeigen sich überzeugt und heben die Kursziele für die Bayer-Aktie an.


23 h. ago
Politics
ID: 7967577262582143964


Similar News expand_more


Politics
Military
Politics
Politics
Politics
Politics
Economics
Politics
Military
Politics
Politics
Politics
Science
Space
Politics
Politics
Politics
Politics
Politics
Crime
Politics
Politics
Real Estate
Politics
Politics
Politics
Technology
Politics
Automotive
Politics
Politics
Politics
Politics
Automotive
Economics
Politics
Sport
Politics
Technology
Politics
Politics
Weather
Politics
Politics
Entertainment
Economics
Military
Politics
Technology
Politics
Politics
Politics
Politics
Politics
Politics
Politics
Politics
Politics
Politics
Science
Science
Crime
Politics
Politics
Politics
Politics
Crime
Politics
Economics
Politics
Politics
Politics
Science
Politics
Politics
Politics
Military
Technology
Politics
Technology
Politics
Science
Politics
Politics
Economics
Military
Politics
Science
Politics
Politics
Politics
Sport
Sport
Economics
Politics
Politics
Politics
Technology
Politics
Add Watch Country

arrow_drop_down